OncologyTwo-pill combination helped lung cancer patients outlive chemo
Adding savolitinib to osimertinib extended median survival from 12.9 to 17.8 months against chemotherapy in EGFR lung cancer driven by high MET levels, the SAFFRON trial found.
25 October 2026